tbuckley/cabot-search huggingface dataset:
Single or two instillations of pirarubicin as prophylaxis for recurrence after transurethral resection of Ta and T1 transitional cell bladder cancer: A prospective, randomized controlled study.
Authors: Takashi Saika, Tomoyasu Tsushima, Yasutomo Nasu, Hiromi Kumon
Journal: Journal of Clinical Oncology (2012)

LBA266 Background: Although single intravesical instillation chemotherapy immediately after transurethral resection (TUR) is the standard treatment for non-muscle-invasive bladder tumors, 40% to 80% of tumors show intravesical recurrence. In this prospective randomized controlled study, we try to evaluate the prophylactic efficacy and safety of twice intravesical instillation using pirarubicin (THP) administered immediately after TUR and on the next day following TUR by comparison with single instillation immediately after TUR. Methods: Between 2005 and 2009, 250 patients with Ta and T1 solitary bladder carcinoma were enrolled in this study. Patients were randomized into two groups. Group A patients were treated with two intravesical instillations of THP 30 mg/50 ml saline immediately after TUR and within 24 hours. Group B patients were treated with single instillation of the same dose immediately after TUR as a control group. The primary endpoint was duration to the first recurrence, and the secondary endpoint was safety. Results: The enrollment was closed on 2009, and the follow-up phase is in process. Of the 250 patients, 125 in Group A and 125 in Group B could be evaluated as full analysis set. One hundred eight male and 17 female were in Group A, on the other hands, one hundred five male and 20 female were in Group B. Eighty-six cases (69%) in group A, and 88 cases (70%) in group B were primary tumor. Fifty-seven cases (46%) in group A, and 56 cases (45%) in group B were small tumor (less than 10mm). There was no difference between backgrounds of both groups. The randomization worked well. In this ad interim report, median follow up was 48 months. Two-year recurrence-free rates were 76.8% in group A and 67.5% in group B. Adverse reactions related to instillation were observed in about 20% of the patients. These toxicities were mild and transient. Only the incidence of frequency in group A was higher than that in group B (20% vs. 8%, p=0.0106). Conclusions: Intravesical instillation of THP 30 mg twice within 24 hours after TUR was effective as prophylactic therapy for non-muscle-invasive cancer with tolerable toxicity problems.
Clinical, Prognostic and Possible Therapeutic Relevance of Angiogenesis in Non-Hodgkin’s Lymphoma.
Authors: Leina Y. Etto, Emilio C.A. Lacerda, Otavio C.G. Baiocchi, Vanderleia C. Silva, Maria Aparecida Dalboni, Riguel J. Inaoka, Fernanda C. Corbi, Antonio C. Alves, Andre L. Vettore, Gisele W.B. Colleoni
Journal: Blood (2007)
Delayed Gastric Emptying in Advanced Parkinson Disease
Authors: Alberto Bestetti, Antonella Capozza, Marco Lacerenza, Luigi Manfredi, Francesca Mancini
Journal: Clinical Nuclear Medicine (2016)

Introduction Gastrointestinal dysfunction is often described in patients with Parkinson disease (PD), and gastrointestinal symptoms are usually attributed to gastroparesis. The consequent delayed gastric emptying (GE) may be an important pharmacokinetic mechanism underlying some of the response fluctuations that develop after long-term levodopa (L-dopa) therapy. The aim of this prospective study was to assess GE time by a liquid meal scintigraphy, in PD patients, and to correlate them with demographic, clinical, and therapeutic data. Methods Scintigraphy with radiolabeled albumin nanocolloids added to acidified orange juice was performed in 51 consecutive PD patients 1 hour after their usual dopaminergic therapy first dose and after a 12-hour fast. Demographic, neurologic, gastrointestinal, and pharmacologic data were collected. Results Fifty-one patients were divided into 2 groups using the cutoff point obtained in normal subjects (40 minutes): group 1 included 29 patients with GE T½ of 27.60 ± 7.30 minutes (normal), group 2 showed a GE T½ of 84.90 ± 53.80 minutes (delayed). The most striking significant difference between the 2 groups was the dopa-decarboxylase inhibitor mean dose that was significantly higher in the group of patients with delayed GE (201.32 ± 97.26 vs 127.65 ± 79.74; P = 0.005). Conclusions The impairment of gastric motility, frequently represented in PD patients, occurs in approximately 42% of patients with motor complications. A mechanism that may explain the GE delay is the effect of L-dopa on dopaminergic receptors in the stomach. Therefore, the dosage of dopa-decarboxylase inhibitor, increasing the L-dopa concentration, may contribute to GE delay and its consequent effect on drug delivery and efficacy.
Factor VIII Proteins Having a Rationally Modified, Immunodominant T-Cell Epitope Demonstrate Normal Procoagulant Activity, Bind To VWF With High Affinity, and Are Markedly Less Stimulatory To FVIII-Specific Human T Cells
Authors: Ruth A. Ettinger, Eddie A. James, Komal Puranik, Arthur R. Thompson, Dana C. Matthews, Kathleen P. Pratt
Journal: Blood (2013)
The Contribution of Signaling Endodomains to CD33-Mediated Killing of Acute Myeloid Leukemia by Natural Killer Cells Transiently Modified with Chimeric Antigen Receptor.
Authors: Jeffrey Friesen, Vladimir Senyukov, Cecele J Denman, Srinivas S. Somanchi, Simon Olivares, Laurence J.N. Cooper, Dean A. Lee
Journal: Blood (2009)
A Minor Genetic Variation In the Granzyme B Gene Predicts Relapse After HLA-Fully-Matched Unrelated Bone Marrow Transplantation for Hematologic Malignancies
Authors: Luis J. Espinoza, Akiyoshi Takami, Kayoko Yamada, Mayu Yamada, Yuki Motohashi, Katsuya Nakata, Eriko Morishita, Shigeki Ohtake, Shinji Nakao
Journal: Blood (2010)
Anti-β2-Microglobulin Monoclonal Antibodies Recruit MHC Class I to and Exclude Growth and Survival Cytokine Receptors from Lipid Rafts and Induce Apoptosis in Myeloma Cells.
Authors: Jing Yang, Xiang Zhang, Ji Wang, Jianfei Qian, Songyoul Hong, Liang Zhang, Luhong Sun, Michael Wang, Larry W. Kwak, Qing Yi
Journal: Blood (2007)
Intravenous Busulfan-Based Conditioning Prior to Allogeneic Stem Cell Transplantation in Adults Patients with AML - An ALWP-EBMT Survey.
Authors: Arnon Nagler, Myriam Labopin, Avichai Shimoni, Donald Bunjes, Pedro Pimentel, Gerard Socie, Karim Boudjedir, Axel R. Zander, A. Torres Gomez, Michele Baccarini, Hakan Goker, Athanasios Fassas, Chantal Kenzey, Benedicte Samey, Zouabi Hamadi, Vanderson Rocha
Journal: Blood (2007)
Adenocarcinomas of the esophagogastric junction: How does surgeon’s assessment influence the fate of patients?
Authors: Dean Bogoevski, Sormeh Mina, Asad Kutup, Maximilian Bockhorn, Matthias Reeh, Thomas Rösch, Jakob Robert Izbicki
Journal: Journal of Clinical Oncology (2012)

92 Background: Due to controversial staging systems, classifying tumors of the esophagogastric junction (EGJ) and the choice of the following surgical therapy remains a delicate affair. Methods: In this study the impact of the preoperative surgical-clinical assessment concerning assorting tumors of the EGJ was evaluated in correlation to the patient’s outcome. We analyzed clinicopathological data from 92 patients who were pre- and intraoperatively classified as distal esophageal cancer (Type I) and thus underwent esophagectomy with gastric tube reconstruction and who afterwards (final histology) in part turned out to be cardia/gastric cancers (Type II). Results: Patients with Type II cancers showed significantly more frequent lymphonodal metastasis (p=0.022) and higher recurrence rates (p=0.01), especially distant metastatic recurrence (p=0.03). Cancer-related death was also significantly higher (p=0.002) and recurrence-free survival was significantly shorter (median: 22 vs. 57 months, p=0.027). Also the thoracoabdominal approach (TA) had a favourable influence on patients’ outcome compared to the transhiatal approach (TH). Conclusions: The correct preoperative assessment of tumors of the EGJ and the appropriate surgical therapy are crucial for the outcome of the patient. Those patients with Type II cancers might experience a survival benefit by undergoing radical combined esophago (-hemi)gastrectomy with colon interposition.
Australian medical college fights accusations of misconduct in presidential election
Authors: Paul Smith
Journal: BMJ (2016)

The Royal Australasian College of Physicians has rejected calls for an independent inquiry into the way it ran its presidential election in April, saying that an internal investigation it commissioned found that the election was “correctly conducted.”

But critics are adamant that the election should be declared null and void. They allege a string of irregularities in the lead-up to the election and conflicts of interest among the board members chosen by the college to lead the investigation.

Peter Brooks, a professorial fellow at the school of population and global health at Melbourne University, described the investigation and the board’s endorsement of its findings as little more than a whitewash. He expressed disbelief at the college’s refusal to launch an independent inquiry.

“The behaviour of the college over its governance of the election remains a very significant concern,” he told The BMJ . “Failure to agree to an independent review of the process is extraordinary behaviour.”

The college has been under fire throughout the presidential election, the results of which …
Induction of Invariant NKT Cell-Dependent Alloreactivity by Administration of G-CSF after Bone Marrow Transplantation
Authors: Edward S Morris, Kelli P A MacDonald, Rachel D Kuns, Helen M Morris, Tatjana Banovic, Alistair LJ Don, Vanessa Rowe, Angela C Burman, Kate A Markey, Dale I Godfrey, Mark J Smyth, Geoff Hill
Journal: Blood (2008)
Comparing the perioperative management of postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) in patients with pure seminomatous and nonseminomatous germ cell tumors (NSGCT).
Authors: D. J. Pfister, J. Busch, C. Winter, M. Schrader, K. Dieckmann, H. U. Schmelz, P. Albers, A. Heidenreich
Journal: Journal of Clinical Oncology (2011)

230 Background: PC-RPLND is a potentially complicated intervention. By the time the rate of complications and adjunctive surgery increased. Only few data are available concerning PC-RPLND in patients with advanced seminomas and residual retroperitoneal tumour lesions. We examined the intra and postoperative complications as well as the frequency of adjunctive surgeries in patients with seminoma and compared the data to a cohort of patients with NSGCT who underwent PC-RPLND. Methods: In our multicenter retrospective analyses 408 patients underwent PC-RPLND between 1989 and 2010. 47 patients with advanced seminomas and 327 patients with NSGCT. The surgical approach was preferred via a midline incision or a thoracoabdominal approach due to the location of the residual tumour. In one center a laparoscopic approach was preferred. Results: Of the 47 patients with seminoma a total number of 18 adjunctive surgeries were performed in 11 patients (8 nephrectomies, 3 inferior v.cava resections, 3 resections of the abdominal aorta, 2 resections of the colon, one nerv and 2 hepatic resections/biopsies). There was only one major intraoperative complication, injury of the v. cava and two postoperative complications, (prolonged intestinal paralyses). There were no significant differences adjunctive surgeries and postoperative complications (p=0.48 and p=0.133). There were significantly less intraoperative complications in favour of seminomas (p=0.006). Conclusions: PCRLND in seminomas and NSGCT is a demanding surgical intervention. In contrast to other series we did not find significant differences in the two patient groups concerning adjunctive surgeries and postoperative complications. The indication for PCLND in patients with seminoma is limited, but if necessary it can be performed safely in experienced centers. No significant financial relationships to disclose.
GAPDH, YWHAZ, and RRN18S as control reference genes for gene expression studies on renal cell carcinoma (RCC) formaldehyde-fixed paraffin-embedded (FFPE) tissue samples.
Authors: V. Medina Villaamil, S. Vazquez-Estevez, B. Campos, L. Leon Mateos, J. L. Fírvida, M. Ramos, F. J. Afonso, O. Fernández Calvo, M. Valladares Ayerbes, L. M. Antón Aparicio
Journal: Journal of Clinical Oncology (2011)

389 Background: It is mandatory to have a control reference gen (RG) to correctly measure gene expression by real-time quantitative PCR (qPCR). The purpose of this study was to test a panel of 12 RGs (Human Endogenous Control Gene Panel, tataabiocenter) in order to select and validate the most appropriate control genes for expression studies on FFPE RCC tissues. Methods: qPCR followed by Normfinder and geNorm-based analysis was employed (GenEx Standard). The study was performed on 9 selected RCC tumor samples with different local stage (T 1 , T 2 and T 3 ). The most representative RCC histologies were also collected; clear-cell renal cell carcinoma (ccRCC), papillary renal cell carcinoma (pRCC) and cromophobe renal cell carcinoma (cRCC). A commercial pool (Biochain) of 5 cases of normal kidney was analyzed too. All samples were measured in triplicate. Expression levels of RGs: GAPDH, TUBB, PPIA, ACTB, YWHAZ, RRN18S, B2M, UBC, TBP, RPLP, GUSB and HPRT1 were measured by qPCR on a Light Cycler 480 (Roche) utilizing Light Cycler 480 SYBR Green I Master (Roche). Results: The analysis of experimental data showed that RRN18S is the most stable gene found in our FFEP RCC samples followed by GUSB and TBP. In contrast, ACTB was found to be the least stable gene between our samples. GAPDH together with YWHAZ was showed as the pair of genes introducing the least systematic error into data normalization (M-value &lt; 1) needed to conduct expression gene studies further. Conclusions: These data suggest that GAPDH, YWHAZ and RRN18S are the most suitable RGs for gene expression profile studies in FFEP RCC. Standardization of RGs will help us to compare results from translational studies on RCC FFPE samples genes profiling. No significant financial relationships to disclose.
Plasma RNA Is More Reliable Than Peripheral Blood Cells for Monitoring Molecular Response to Imatinib in Patients with Chronic Myeloid Leukemia.
Authors: W. Ma, R. Tseng, M. Gorre, I. Jilani, M. Keating, H. Kantarjian, J. Cortes, S. O’Brien, F. Giles, M. Albitar
Journal: Blood (2005)
AMD107: Efficacy as a Selective Inhibitor of the Tyrosine Kinase Activity of BCR-ABL in Murine Leukemia Models.
Authors: James D. Griffin, Doriano Fabbro, Gabriele Fendrich, Brian Huntly, Sandra Jacob, Andrew Kung, Jurgen Mestan, Ellen Weisberg, D. Gary Gilliland, Paul W. Manley
Journal: Blood (2004)
A phase I dose-escalation study of azacitidine in combination with temozolomide in patients with soft tissue sarcomas.
Authors: I. Matushansky, K. E. Coakley, T. S. Uldrick, R. N. Taub
Journal: Journal of Clinical Oncology (2011)

10073 Background: The response rate in patients with soft tissue sarcomas (STS) treated with the DNA-alkylator temozolomide (TZ) is 15%. DNA methylation dependent silencing of mismatch repair proteins may contribute to TZ resistance by eliminating the tumor cell’s ability to link the recognition of DNA damage caused by alkylating agents with an apoptotic response. Preclinical studies have shown that gene silencing may be reversed with a DNA methyl transferase inhibitor (e.g, azacitidine (AZ)). We hypothesized that sequential AZ treatment followed by TZ would reverse the silencing of mismatch repair proteins in tumors cell, thereby increasing the apoptotic effect of TZ. Methods: Patients with unresectable or metastatic STS, life expectancy >3 months, KPS ≥ 60%, and sufficient hematologic, hepatic, and renal function were enrolled. A standard 3+3 design was used to determine the MTD with levels 1-3 dosed with AZ (SQ days 1-5) 25 mg/m2, 50 mg/m2, and 75 mg/m2 respectively, and TZ (PO days 8-12) constant at 200 mg/m2. Results: Twelve patients (9 male 3 female) were enrolled: 3 in cohort 1, 3 in cohort 2, and 6 in cohort 3. Ages ranged from 41-81, with a median of 57. Diagnoses included: liposarcoma (5), synovial cell sarcoma (1), granular cell tumor (1), desmoplastic round cell tumor (1), pleomorphic sarcoma (1), endometrial stromal sarcoma (1), and leiomyosarcoma (2). The most common toxicities were nausea, thrombocytopenia, hypoalbuminemia, hyperglycemia, and elevated alkaline phosphatase. One DLT (grade 4 neutropenia) was observed at dose level 3. The recommended Phase II dose was determined to be AZ 75 mg/m2 and TZ200 mg/m2. All 6 patients treated on the lower dose levels showed progressive disease after 2 cycles. Of those treated at the highest dose, 2 patients demonstrated progressive disease, 2 demonstrated stable disease and 1 demonstrated a partial response. Conclusions: The combination of TZ plus AZ was well tolerated, and the recommended Phase II dose for the combination is consistent with the conventional single agent doses. An expansion study is being implemented to allow for further analysis of the safety and efficacy of this combination of drugs in patients with STS.
A Novel and Personalized Method Using Simulation for Predicting Effective Therapeutics for Waldenströms Macroglobulinemia
Authors: Abdel Kareem Azab, Aneel Paulus, Feda Azab, Sharoon Akhtar, Shireen Vali, Ansu Kumar, Neeraj Kumar Singh, Shweta Kapoor, Taher Abbasi, Asher Chanan-Khan, Kasyapa S. Chitta
Journal: Blood (2014)
A phase I trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases (ILM) from colorectal cancer (CRC).
Authors: Deepa Magge, Amer H Zureikat, David L. Bartlett, Matthew Peter Holtzman, Haroon Choudry, Jan H. Beumer, Julianne L. Holleran, S. Strychor, James F. Pingpank, Herbert Zeh
Journal: Journal of Clinical Oncology (2012)

283 Background: IHP is a proven approach for regional delivery of chemotherapy in patients with unresectable ILM. This study sought to determine safety and MTD of administering 5FU in combination with fixed dose oxaliplatin via IHP. Methods: Prospective Phase I dose escalation with standard 3x3 dosing. Subjects with unresectable ILM from CRC scheduled to receive an HAI pump were eligible. IHP employed fixed dose oxaliplatin (previously established)with escalating doses of 5FU. 1 endpoint was to determine MTD for this combination. 2 endpoints were response to IHP alone, PFS, and OS for IHP + HAI-FUDR. Systemic and IHP plasma PK of 5FU, anabolites, total, and free platinum were determined by validated assays. Results: Between Aug 2007 - Mar 2011, 11 subjects were enrolled. All patients received at least one line of pre-IHP systemic chemotherapy. There were 4 Grade 3 SAE (36.3%) and no grade 4 events. 2 DLTs occurred in the second dose cohort of 300mg/m 2 . Dose escalation was terminated and 200mg/m 2 5FU was determined to be the MTD. There was 1 DLT in the dose de-escalating phase of 200mg/m 2 . At first follow-up, 9 pts (82%) had a partial response, while 2 (18%) had stable disease. 64% of pts had a &gt;50% decrease in CEA level. Actuarial 1 and 2 year survival was 100% and 75% respectively, with median follow-up of 23 mos. IHP exposures (AUC 0-60min ) were 10.9±4.5 µgPt·h/mL (platinum), 49.3±30.7 µg·h/mL 5FU (DL1) and 70.5±35.5 µg·h/mL 5FU (DL2). Free platinum represented 82±14% of total platinum. Systemic exposure (AUC 0-inf ) relative to IHP exposure was negligible for both total platinum (1.1±1.5%) and 5FU (0.09±0.10%). IHP exposure to metabolites relative to 5FU was 4.9±2.5% for FUrd and 0.23±0.14% for FdUrd, respectively. Conclusions: MTD for IHP with 5FU and oxaliplatin is 200 mg/m 2 and 40mg/m 2 respectively. Systemic exposure to the agents was minimal. The response and survival observed in this dose escalation study warrants assessment in a larger phase II trial. [Table: see text]
Post-transplant Treatment of Severe Recurrent Hepatitis C (HCV) with Daclatasvir and Sofosbuvir Plus or Minus Ribavirin
Authors: Natalie H. Bzowej, Shobha Joshi, George Therapondos, Nigel Girgrah, Gia Tyson, Inna Goldvarg-Abud, Jennifer B. Scheuermann, Humberto E. Bohorquez, Ari J. Cohen, Ian C. Carmody, Trevor W. Reichman, David S. Bruce, George E. Loss
Journal: Hepatology (2014)
Incidence and risk of congestive heart failure risk in renal cell cancer (RCC) and non-RCC patients treated with sunitinib.
Authors: C. J. Richards, Y. Je, F. A. Schutz, S. M. Dallabrida, J. J. Moslehi, T. K. Choueiri
Journal: Journal of Clinical Oncology (2011)

316 Background: Sunitinib is a multitargeted receptor tyrosine kinase inhibitor that is widely used in the treatment of renal cell cancer (RCC) and several other malignancies. Congestive heart failure (CHF) has been reported with sunitinib, but the overall incidence and relative risk (RR) remain undefined. We preformed an up-to-date comprehensive meta-analysis to determine the risk of developing serious CHF in patients with both RCC and non-RCC tumors treated with sunitinib. Methods: Medline databases were searched for articles from January 1966 to September 2010. Eligible studies were limited to phase II and III trials of sunitinib in cancer patients with any primary tumor type and adequate safety profile reporting. Statistical analyses were conducted to calculate the summary incidence, RR and 95% confidence intervals (CI), using random-effects models. Results: A total of 5,497 patients were included. Overall incidence for all-grade and high-grade CHF in sunitinib-treated patients was 4.9% (95% CI, 1.6–14.1%) and 1.8% (95% CI, 0.8–3.9%), respectively. The RR of all-grade and high-grade CHF in sunitinib-treated patients compared to placebo-treated ones was 1.81 (95% CI, 1.30–2.50; p&lt;0.0001) and 3.17 (95% CI, 1.12–8.97; p=0.030), respectively. On subgroup analysis there was no difference observed in the CHF incidence for RCC vs. non-RCC patients. No evidence of publication bias was observed. Conclusions: This is the first comprehensive report to demonstrate that sunitinib use is associated with an increased risk of significant heart failure in cancer patients. [Table: see text]
Origins of emotional consciousness
Authors: Hans L Melo, Timothy R Koscik, Thalia H Vrantsidis, Georgia Hathaway, William A Cunningham
Journal: Behavioral and Brain Sciences (2016)

Abstract While the field of emotions research has benefited from new developments in neuroscience, many theoretical questions remain unsolved. We propose that integrating our iterative reprocessing (IR) framework with the passive frame theory (PFT) may help unify competing theoretical perspectives of emotion. Specifically, we propose that PFT and the IR framework offer a point of origin for emotional experience.
Clarithromycin Elevates the Plasma Concentration of Lenalidomide Via Inhibition of MDR1
Authors: Naoki Takezako, Masatomo Miura, Akihisa Nagata, Naohiro Sekiguchi, Takenori Niioka, Seiji Shida, Takahiro Kobayashi, Maiko Abumiya, Akiyoshi Miwa, Naoto Takahashi
Journal: Blood (2014)